Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report.

Schriber JR, Hari PN, Ahn KW, Fei M, Costa LJ, Kharfan-Dabaja MA, Angel-Diaz M, Gale RP, Ganguly S, Girnius SK, Hashmi S, Pawarode A, Vesole DH, Wiernik PH, Wirk BM, Marks DI, Nishihori T, Olsson RF, Usmani SZ, Mark TM, Nieto YL, D'Souza A.

Cancer. 2017 Aug 15;123(16):3141-3149. doi: 10.1002/cncr.30747. Epub 2017 May 4.

PMID:
28472539
2.

A rare case of central nervous system amyloidoma treated with fractionated radiotherapy.

Meier T, Hazenfield JM, Girnius S, Hagen M, Warnick RE, Kharofa J.

J Neurosurg. 2017 Aug;127(2):338-341. doi: 10.3171/2016.7.JNS1690. Epub 2016 Sep 30.

PMID:
27689460
3.

Recent advances in understanding multiple myeloma.

Dhakal B, Girnius S, Hari P.

F1000Res. 2016 Aug 23;5. pii: F1000 Faculty Rev-2053. doi: 10.12688/f1000research.8777.1. eCollection 2016. Review.

4.

A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation.

Girnius SK, Lee S, Kambhampati S, Rose MG, Mohiuddin A, Houranieh A, Zimelman A, Grady T, Mehta P, Behler C, Hayes TG, Efebera YA, Prabhala RH, Han A, Yellapragada SV, Klein CE, Roodman GD, Lichtenstein A, Munshi NC.

Br J Haematol. 2015 Apr;169(1):36-43. doi: 10.1111/bjh.13243. Epub 2015 Jan 8.

PMID:
25572917
5.

Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.

Mughal TI, Girnius S, Rosen ST, Kumar S, Wiestner A, Abdel-Wahab O, Kiladjian JJ, Wilson WH, Van Etten RA.

Leuk Lymphoma. 2014 Sep;55(9):1968-79. doi: 10.3109/10428194.2013.863307. Epub 2014 Feb 17. Review.

6.

Individualized therapy in multiple myeloma: are we there?

Girnius S, Munshi NC.

Semin Oncol. 2013 Oct;40(5):567-76. doi: 10.1053/j.seminoncol.2013.08.001.

PMID:
24135401
7.

New hematologic response criteria predict survival in patients with immunoglobulin light chain amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation.

Girnius S, Seldin DC, Cibeira MT, Sanchorawala V.

J Clin Oncol. 2013 Jul 20;31(21):2749-50. doi: 10.1200/JCO.2013.48.7736. Epub 2013 Jun 17. No abstract available.

PMID:
23775968
8.

A new lysozyme tyr54asn mutation causing amyloidosis in a family of Swedish ancestry with gastrointestinal symptoms.

Girnius S, Skinner M, Spencer B, Prokaeva T, Bartholomew C, O'Hara C, Seldin DC, Connors LH.

Amyloid. 2012 Dec;19(4):182-5. doi: 10.3109/13506129.2012.723074. Epub 2012 Sep 14.

PMID:
22978355
9.

Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis.

Girnius S, Seldin DC, Skinner M, Finn KT, Quillen K, Doros G, Sanchorawala V.

Ann Hematol. 2010 Jun;89(6):579-84. doi: 10.1007/s00277-009-0874-8. Epub 2009 Dec 10.

PMID:
20012043
10.

Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease.

Girnius S, Seldin DC, Skinner M, Finn KT, Quillen K, Doros G, Sanchorawala V.

Haematologica. 2009 Jul;94(7):1029-32. doi: 10.3324/haematol.2008.001925. Epub 2009 May 19.

11.

Treatment of refractory radiation-induced hemorrhagic proctitis with hyperbaric oxygen therapy.

Girnius S, Cersonsky N, Gesell L, Cico S, Barrett W.

Am J Clin Oncol. 2006 Dec;29(6):588-92.

PMID:
17148996
12.

Male breast cancer: a gender issue.

Nahleh Z, Girnius S.

Nat Clin Pract Oncol. 2006 Aug;3(8):428-37. Review.

PMID:
16894388
13.

Support of trigeminal sensory neurons by nonneuronal p75 neurotrophin receptors.

Fan L, Girnius S, Oakley B.

Brain Res Dev Brain Res. 2004 May 19;150(1):23-39.

PMID:
15126035

Supplemental Content

Loading ...
Support Center